TheraRadar
Data updated: Jul 17, 2026

MINODYL (minoxidil) · QUANTUM PHARMICS

Trial Activity: Expansion 4 active trials
Cardiovascular Approved 1988-07-15

MINODYL is FDA-approved to treat 1 condition (same as MINOXIDIL).

Source: FDA Label

Development Insights

Duke University conducting 1 trials (14%)
10 indications explored (Broad Platform)
androgenetic alopecia (3 trials)
breast reconstruction (1 trials)
perfusion; complications (1 trials)

Details

Status
Discontinued
First Approved
1988-07-15
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: MINOXIDIL

MINODYL Approval History

1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
3 FDA actions from 1988 to 1988
Jul 1988 SUPPL
Mfg · Manufacturing (CMC)

What MINODYL Treats

1 indications

MINODYL is approved for 1 conditions . These indications span multiple therapeutic areas including oncology, immunology, and more.

Same approved indications as MINOXIDIL (same active ingredient).

Source: FDA Label
📋

Clinical Trial Registry

8 trials
Trial Sponsor ID Phase Status Title
NCT06924632 SAM-002 Ph 3 completed Efficacy & Safety of Minoxidil SL Tablets in Men With AGA
NCT07264790 Pro00116354 Ph 1 recruiting Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon
NCT04207931 CCCA IRB00043796 Ph 4 recruiting Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study
NCT07273799 mina 02-TERC/NHRC-SZH/Int-SC/651 Ph 3 not yet recruiting Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia
NCT00876200 Williams results posted 2006.437/30 Ph 2 completed Efficacy of Minoxidil in Children With Williams-Beuren Syndrome
NCT01319370 CRC-AGA02 2010-018291-25 Ph 2 completed Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia
NCT00958750 CRC-AGA01 EudraCT: 2008-001770-33 Ph 3 completed Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia
NCT07594678 OSU-24393 NCI-2026-02583 Ph 2 not yet recruiting Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

MINODYL FDA Label Details

Indications & Usage

MINODYL is FDA-approved to treat 1 condition — same approved indications as MINOXIDIL.

Track MINODYL with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.

How We Calculate These Metrics

Trial Activity Stage

Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.

Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.

  • Growth: High proportion of early-phase trials (Phase 1/2), active development
  • Expansion: Significant Phase 3 activity, approaching or pursuing approvals
  • Mature: Substantial Phase 4 post-marketing studies
  • Stable: Mixed phase distribution, steady development
  • Declining: Low active trial ratio, reduced R&D investment